AGO2通过抑制瘤IFN-马反应依赖的CD8+ T细胞免疫力来调解免疫疗法失败
Yuzhao Wang1, Zibin Chen1, Ke Liang1
1Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
阿尔戈纳特2 (AGO2) 通过抑制干扰素- (IFN-γ) 信号,阻碍癌症免疫疗法. 在临床前模型中,抑制AGO2或miR-1246可以恢复免疫反应,并提高治疗疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 干扰素- (IFN-γ) 对于抗瘤免疫力和免疫治疗成功至关重要.
- 阿尔戈纳特2 (AGO2) 通过小RNAs调节基因表达.
- 瘤对IFN-γ和免疫疗法的耐药性仍然是一个临床挑战.
研究的目的:
- 研究AGO2在瘤对IFN-γ和免疫治疗的反应中的作用.
- 阐明AGO2影响IFN-γ信号传递的分子机制.
- 评估针对AGO2-miR-1246轴的治疗策略.
主要方法:
- 对AGO2表达与瘤反应的相关性分析.
- 涉及miR-1246,AGO2,STAT1和PTPN6.6的机制研究
- 用AGO2抑制剂 (BCI-137) 或miR-1246对抗治疗的临床前癌症模型.
- 免疫细胞透,激活和细胞毒性的评估.
主要成果:
- AGO2表达与瘤对IFN-γ和免疫治疗的反应相反相关.
- IFN-γ上调 miR-1246,它与 AGO2 复合,以稳定 PTPN6 mRNA.
- 这种复合物抑制STAT1酸化,减少CXCLs,ISGs和HLA表达,促进免疫逃避.
- 抑制AGO2或miR-1246恢复了IFN-γ的敏感性,并增强了抗瘤CD8+T细胞的反应.
结论:
- 通过抑制关键的免疫信号通路,AGO2和miR-1246通过介导对IFN-γ和免疫治疗的抵抗.
- 准AGO2-miR-1246相互作用是克服免疫疗法耐药性的有希望的策略.
- 通过抑制AGO2或miR-1246恢复IFN-γ反应,可以增强抗瘤免疫力和治疗效率.
更多相关视频
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
相关概念视频
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses
The Tumor Microenvironment
